Sangamo BioSciences | SGMO - Operating Expenses


Sangamo BioSciences reported $33.87M in Operating Expenses for its fiscal quarter ending in June of 2024.





Operating Expenses Change Date
Alaunos Therapeutics USD 1.19M 148K Sep/2025
Alnylam Pharmaceuticals USD 898.54M 66.78M Mar/2026
Alterity Therapeutics Limited AUD 8.67M 893.38K Dec/2025
Amgen USD 4.78B 1.12B Mar/2026
Bayer EUR 10.33B 126M Dec/2025
BioCryst Pharmaceuticals USD 146.17M 534.06M Dec/2025
Biogen USD 1.96B 69.6M Mar/2026
BioMarin Pharmaceutical USD 636.56M 39.61M Mar/2026
Cipla INR 60.98B 1.06B Dec/2025
Clal Biotechnology ILS 5.15M 9.47M Dec/2022
Compugen USD 11.29M 1.51M Dec/2025
CSL USD 5.7B 2.82B Dec/2025
Gilead Sciences USD 4.96B 707M Dec/2025
GlaxoSmithKline GBP 5.34B 1.85B Mar/2026
Grifols EUR 1.99B 217.4M Dec/2025
Ionis Pharmaceuticals USD 364M 54M Mar/2026
J&J USD 17.44B 1.53B Mar/2026
Karyopharm Therapeutics USD 51.92M 9.9M Dec/2025
Merck USD 18.17B 8.01B Mar/2026
Novartis USD 9.29B 507M Mar/2026
Omeros USD 59.16M 20.13M Jun/2024
Pfizer USD 90.1B 77.19B Mar/2026
Roche Holding CHF 21.01B 10.84B Dec/2025
Sangamo BioSciences USD 33.87M 12.89M Jun/2024
Sanofi EUR 9.31B 1.2B Mar/2026
Sarepta Therapeutics USD 853.02M 390.78M Dec/2025
Tectonic Therapeutic USD 21.52M 374K Dec/2025
Ultragenyx Pharmaceutical USD 321M 9.82M Dec/2025
Vertex Pharmaceuticals USD 1.85B 78.6M Mar/2026